Akero CDO Sells $540K in Stock Following Options Exercise

Insider Trading Activity Report: Catriona Yale, Chief Development Officer of Akero Therapeutics (NASDAQ: AKRO), executed multiple transactions on June 16, 2025, as part of a pre-established Rule 10b5-1 trading plan from May 24, 2024.

Rhea-AI Filing Summary

Insider Trading Activity Report: Catriona Yale, Chief Development Officer of Akero Therapeutics (NASDAQ: AKRO), executed multiple transactions on June 16, 2025, as part of a pre-established Rule 10b5-1 trading plan from May 24, 2024.

Transaction Details:

• Exercised 10,000 stock options at $21.10 per share
• Subsequently sold a total of 10,000 shares in three tranches: - 6,210 shares at avg. price $53.78 - 2,895 shares at avg. price $54.80 - 895 shares at avg. price $55.52
• Following these transactions, Yale holds 92,231 shares directly

The transactions resulted in a reduction of Yale's holdings from 102,231 to 92,231 shares. The exercise and sale pattern suggests a typical insider stock option monetization strategy, with the sales prices representing a significant premium over the option exercise price.

Insider Trade Summary

Exercise and Sale: 10,000 shares ($331K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Yale Catriona

Role Chief Development Officer

Sold 10,000 shs ($542K)

Approx. gross sale proceeds $542K

Approx. exercise cost $211K

Approx. pre-tax spread $331K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	$0.00
Exercise	Common Stock	10,000	$21.10	$211K
Sale	Common Stock	6,210	$53.78	$334K
Sale	Common Stock	2,895	$54.799	$159K
Sale	Common Stock	895	$55.519	$50K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 92,231 shares (Direct)

Footnotes (5)

1. F1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2024, previously adopted by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.40 to $54.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.40 to $55.38, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $55.43 to $55.68, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
5. F5. The options are vested and currently exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AKRO's Chief Development Officer Catriona Yale report on June 16, 2025?

On June 16, 2025, AKRO's Chief Development Officer Catriona Yale exercised 10,000 stock options at $21.10 per share and subsequently sold a total of 10,000 shares in three transactions: 6,210 shares at an average price of $53.78, 2,895 shares at $54.799, and 895 shares at $55.519.

How many shares does Catriona Yale own of AKRO after the reported transactions?

Following the reported transactions, Catriona Yale directly owns 92,231 shares of AKRO common stock.

Was AKRO insider Catriona Yale's stock sale planned in advance?

Yes, the transactions were executed pursuant to a Rule 10b5-1 trading plan that was previously adopted by Yale on May 24, 2024, indicating these were pre-planned sales rather than spontaneous trading decisions.

What was the price range of AKRO shares sold by Catriona Yale on June 16, 2025?

The shares were sold in multiple transactions with prices ranging from $53.40 to $55.68. Specifically, the first batch ranged from $53.40 to $54.37, the second batch from $54.40 to $55.38, and the final batch from $55.43 to $55.68.

How many stock options does Catriona Yale have remaining for AKRO after exercising 10,000 options?

After exercising 10,000 options, Yale has 0 remaining stock options from this particular grant (which had an expiration date of 12/07/2031 and an exercise price of $21.10).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/20/2025 - 09:22 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yale Catriona

(Last) (First) (Middle)

601 GATEWAY BOULEVARD

SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		M(1)		10,000	A	$21.1	102,231	D
Common Stock	06/16/2025		S(1)		6,210	D	$53.78(2)	96,021	D
Common Stock	06/16/2025		S(1)		2,895	D	$54.799(3)	93,126	D
Common Stock	06/16/2025		S(1)		895	D	$55.519(4)	92,231	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$21.1	06/16/2025		M(1)			10,000	(5)	12/07/2031	Common Stock	29,073	$0	0	D

Explanation of Responses:

1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2024, previously adopted by the Reporting Person.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.40 to $54.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.40 to $55.38, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $55.43 to $55.68, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

5. The options are vested and currently exercisable.

	/s/ Jonathan Young, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.